It also should be noted that GIST, a tumor generally bearing ANO1 positivity, was known for poor immunotherapeutic responses.[31] Among four GIST patients treated with immunotherapy in our center during 2018–2022 (Figure S1G, Supporting Information), immunohistochemistry (IHC) indicated that ANO1‐negative cases displayed potentially better irPFS/irOS than ANO1‐positive cases (Figure S1H, Supporting Information). Here, ANO1 is linked to gastrointestinal stromal tumor.